Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma.
TLR4
follicular lymphoma
glucopyranosyl lipid A
immunotherapy
pembrolizumab
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
pubmed:
7
12
2021
medline:
21
4
2022
entrez:
6
12
2021
Statut:
ppublish
Résumé
Intratumoral injection of G100, a toll-like receptor 4 (TLR4) agonist, was shown pre-clinically to stimulate anti-tumor immune responses and tumor regression. This open-label, multicenter, phase 1/2 trial evaluated the safety, tolerability, and preliminary efficacy of intratumoral G100 injections following localized low-dose radiation in patients with follicular lymphoma (ClinicalTrials.gov #NCT02501473). The study was comprised of a G100 dose escalation (5 or 10 µg/dose, or 20 µg/dose for large tumors); a randomized component comparing G100 to G100 plus pembrolizumab; and G100 20 µg/dose expansion. Adverse events grade ≥3 were uncommon in patients treated with G100, and no unexpected toxicities were observed when combined with pembrolizumab. G100 20 µg (
Identifiants
pubmed: 34865586
doi: 10.1080/10428194.2021.2010057
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
TLR4 protein, human
0
Toll-Like Receptor 4
0
pembrolizumab
DPT0O3T46P
Banques de données
ClinicalTrials.gov
['NCT02501473']
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM